Identification of Serum Amyloid A Protein As a Potentially Useful Biomarker to Monitor Relapse of Nasopharyngeal Cancer by Serum Proteomic Profiling
10.1158/1078-0432.ccr-0413-3
Crossref journal-article
American Association for Cancer Research (AACR)
Clinical Cancer Research (1086)
Abstract

Abstract Purpose: Nasopharyngeal cancer (NPC) is a common cancer in Hong Kong, and relapse can occur frequently. Using protein chip profiling analysis, we aimed to identify serum biomarkers that were useful in the diagnosis of relapse in NPC. Experimental Design: Profiling analysis was performed on 704 sera collected from 42 NPC patients, 39 lung cancer patients, 30 patients with the benign metabolic disorder thyrotoxicosis (TX), and 35 normal individuals (NM). Protein profile in each NPC patient during clinical follow up was correlated with the relapse status. Results: Profiling analysis identified two biomarkers with molecular masses of 11.6 and 11.8 kDa, which were significantly elevated in 22 of 31 (71%) and 21 of 31 (68%) NPC patients, respectively, at the time of relapse (RP) as compared with 11 patients in complete remission (CR; RP versus CR, P = 0.009), 30 TX (RP versus TX, P < 0.001), or 35 NM (RP versus NM, P < 0.001). The markers were also elevated in 16 of 39 (41%) lung cancer patients at initial diagnosis. By tryptic digestion, followed by tandem mass spectrometry fragmentation, the markers were identified as two isoforms of serum amyloid A (SAA) protein. Monitoring the patients longitudinally for SAA level both by protein chip and immunoassay showed a dramatic SAA increase, which correlated with relapse and a drastic fall correlated with response to salvage chemotherapy. Serum SAA findings were compared with those of serum Epstein-Barr virus DNA in three relapsed patients showing a similar correlation with relapse and chemo-response. Conclusions: SAA could be a useful biomarker to monitor relapse of NPC.

Bibliography

Cho, W. C. S., Yip, T. T. C., Yip, C., Yip, V., Thulasiraman, V., Ngan, R. K. C., Yip, T.-T., Lau, W.-H., Au, J. S. K., Law, S. C. K., Cheng, W.-W., Ma, V. W. S., & Lim, C. K. P. (2004). Identification of Serum Amyloid A Protein As a Potentially Useful Biomarker to Monitor Relapse of Nasopharyngeal Cancer by Serum Proteomic Profiling. Clinical Cancer Research, 10(1), 43–52.

Authors 13
  1. William C. S. Cho (first)
  2. Timothy T. C. Yip (additional)
  3. Christine Yip (additional)
  4. Victor Yip (additional)
  5. Vanitha Thulasiraman (additional)
  6. Roger K. C. Ngan (additional)
  7. Tai-Tung Yip (additional)
  8. Wai-Hon Lau (additional)
  9. Joseph S. K. Au (additional)
  10. Stephen C. K. Law (additional)
  11. Wai-Wai Cheng (additional)
  12. Victor W. S. Ma (additional)
  13. Cadmon K. P. Lim (additional)
References 46 Referenced 158
  1. Hong Kong Hospital Authority. . Cancer Incidence and Mortality in Hong Kong 1998–1999, 38-39, Hong Kong Cancer Registry  2000.
  2. Ho J. H. C. Nasopharyngeal carcinoma (NPC). Adv. Cancer Res., 15: 57-92,  1972. (10.1016/S0065-230X(08)60372-3)
  3. Lee A. W., Poon Y. F., Foo W., Law S. C., Cheung F. K., Chan D. K., Tung S. Y., Thaw M., Ho J. H. C. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976–1985: overall survival and patterns of failure. Int. J. Radiat. Oncol. Biol. Phys., 23: 261-270,  1992. (10.1016/0360-3016(92)90740-9)
  4. Leung S. F., Teo P. M., Shiu W. W., Tsao S. Y., Leung T. W. Clinical features and management of distant metastases of nasopharyngeal carcinoma. J. Otolaryngol., 20: 27-29,  1991.
  5. Ngan R. K. C., Lau W. H., Yip T. T. C., Cho W. C. S., Cheng W. W., Lim C. K., Wan K. K., Chu E., Joab I., Grunewald V., Poon Y. F., Ho J. H. C. Remarkable application of serum EBV EBER-1 in monitoring response of nasopharyngeal cancer patients to salvage chemotherapy. Ann. N Y Acad. Sci., 945: 73-79,  2001. (10.1111/j.1749-6632.2001.tb03866.x)
  6. Ngan R. K. C., Yip T. T. C., Cheng W. W., Chan J. K. C., Cho W. C. S., Ma V. W. S., Wan K. K., Au S. K., Law C. K., Lau W. H. Circulating Epstein-Barr virus DNA in serum of patients with lymphoepithelioma-like carcinoma of the lung: a potential surrogate marker for monitoring disease. Clin. Cancer Res., 8: 986-994,  2002.
  7. Fung E. T., Thulasiraman V., Weinberger S. R., Dalmasso E. A. Protein biochips for differential profiling. Curr. Opin. Biotechnol., 12: 65-69,  2001. (10.1016/S0958-1669(00)00167-1)
  8. Petricoin E. F., III, Ardekani A. M., Hitt B. A., Levine P. J., Fusaro V. A., Steinberg S. M., Mills G. B., Simone C., Fishman D. A., Kohn E. C., Liotta L. A. Use of proteomic patterns in serum to identify ovarian cancer. Lancet, 359: 572-577,  2002. (10.1016/S0140-6736(02)07746-2)
  9. Poon Y. F., Lau W. H. Current management of carcinoma of the nasopharynx Tobias J. S. Thomas P. R. M. eds. . Current Radiation Oncology, 3: 146-176, Oxford University Press New York  1998.
  10. Ngan R. K., Yiu H. H., Lau W. H., Yau S., Cheung F. Y., Chan T. M., Kwok C. H., Chiu C. Y., Au S. K., Foo W., Law C. K., Tse K. C. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a Phase II study. Ann. Oncol., 13: 1252-1258,  2002. (10.1093/annonc/mdf200)
  11. Hutches T. W., Yip T. T. New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Commun. Mass Spectrom., 7: 576-580,  1993. (10.1002/rcm.1290070703)
  12. Cleveland D. W., Fischer S. G., Kirschner M. W., Laemmli U. K. Peptide mapping by limited proteolysis in sodium dodecyl sulfate and analysis by gel electrophoresis. J. Biol. Chem., 252: 1102-1106,  1977. (10.1016/S0021-9258(19)75212-0)
  13. Baudys M., Foundling S., Pavlik M., Blundell T., Kostka V. Protein chemical characterization of Mucor pusillus aspartic proteinase amino acid sequence homology with the other aspartic proteinases disulfide bond arrangement and site of carbohydrate attachment. FEBS Lett., 235: 271-274,  1988. (10.1016/0014-5793(88)81277-8)
  14. Fournier I., Chaurand P., Bolbach G., Lutzenkirchen F., Spengler B., Tabet J. C. Sequencing of a branched peptide using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. J. Mass Spectrom., 35: 1425-1433,  2000. (10.1002/1096-9888(200012)35:12<1425::AID-JMS77>3.0.CO;2-C)
  15. Perkins D. N., Pappin D. J., Creasy D. M., Cottrell J. S. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis, 20: 3551-3567,  1999. (10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2)
  16. Fung E., Enderwich C. ProteinChip clinical proteomics: computational challenges and solutions. Biotechniques, 32: S34-S41,  2002. (10.2144/mar0205)
  17. Krauth J. The interpretation of significance tests for independent and dependent samples. J. Neurosci. Methods, 9: 269-281,  1983. (10.1016/0165-0270(83)90058-4)
  18. Ho J. H. C. Stage classification of nasopharyngeal carcinoma: a review De The G. Eto Y. eds. . Nasopharyngeal Carcinoma: Etiology and Contro., 99-113, IARC Lyon, France IARC Scientific Publ. No. 20. 1978.
  19. Lo Y. M., Chan L. Y., Lo K. W., Leung S. F., Zhang J., Chan A. T., Lee J. C., Hjelm N. M., Johnson P. J., Huang D. P. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res., 59: 1188-1191,  1999.
  20. Wright G. L., Jr. SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis. Expert Rev. Mol. Diagn., 2: 549-563,  2002. (10.1586/14737159.2.6.549)
  21. Issaq H. J., Veenstra T. D., Conrads T. P., Felschow D. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem. Biophys. Res. Commun., 292: 587-592,  2002. (10.1006/bbrc.2002.6678)
  22. Weinberger S. R., Dalmasso E. A., Fung E. T. Current achievements using ProteinChip Array technology. Curr. Opin. Chem. Biol., 6: 86-91,  2002. (10.1016/S1367-5931(01)00282-4)
  23. Xiao Z., Adam B. L., Cazares L. H., Clements M. A., Davis J. W., Schelhammer P. F., Dalmasso E. A., Wright G. L., Jr. Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res., 61: 6029-6033,  2001.
  24. Adam B. L., Qu Y., Davis J. W., Ward M. D., Clements M. A., Cazares L. H., Semmes O. J., Schelhammer P. F., Yasui Y., Feng Z., Wright G. L., Jr. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res., 62: 3609-3614,  2002.
  25. Wu W., Tang X., Hu W., Lotan R., Hong W. K., Mao L. Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimensional electrophoresis and mass spectrometry. Clin. Exp. Metastasis, 19: 319-326,  2002. (10.1023/A:1015515119300)
  26. Valle R. P., Chavany C., Zhukov T. A., Jendoubi M. New approaches for biomarker discovery in lung cancer. Expert Rev. Mol. Diagn., 3: 55-67,  2003. (10.1586/14737159.3.1.55)
  27. Li J., Zhang Z., Rosenzweig J., Wang Y. Y., Chan D. W. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin. Chem., 48: 1296-1304,  2002. (10.1093/clinchem/48.8.1296)
  28. Paweletz C. P., Trock B., Pennanen M., Tsangaris T., Magnant C., Liotta L. A., Petricoin E. F., III. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis. Markers, 17: 301-307,  2001. (10.1155/2001/674959)
  29. Rosty C., Christa L., Kuzdzal S., Baldwin W. M., Zahurak M. L., Carnot F., Chan D. W., Canto M., Lillemoe K. D., Cameron J. L., Yeo C. J., Hruban R. H., Goggins M. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res., 62: 1868-1875,  2002.
  30. Ardekani A. M., Liotta L. A., Petricoin E. F., III. Clinical potential of proteomics in the diagnosis of ovarian cancer. Expert Rev. Mol. Diagn., 2: 312-320,  2002. (10.1586/14737159.2.4.312)
  31. Yamada T. Serum amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness. Clin. Chem. Lab. Med., 37: 381-388,  1999. (10.1515/CCLM.1999.063)
  32. Watson G., See C. G., Woo P. Use of somatic cell hybrids and fluorescence in situ hybridization to localize the functional serum amyloid A (SAA) genes to chromosome 11p15.4-p15.1 and the entire SAA superfamily to chromosome 11p15. Genomics, 23: 694-696,  1994. (10.1006/geno.1994.1559)
  33. Raynes J. G., Eagling S., McAdam K. P. Acute-phase protein synthesis in human hepatoma cells. Differential regulation of serum amyloid A (SAA) and haptoglobin by interleukin-1 and interleukin-6. Clin. Exp. Immunol., 83: 488-491,  1991. (10.1111/j.1365-2249.1991.tb05666.x)
  34. Bausserman L. L., Herbert P. N., Rodger R., Nicolosi R. J. Rapid clearance of serum amyloid A from high-density lipoproteins. Biochim. Biophys. Acta, 792: 186-191,  1984. (10.1016/0005-2760(84)90221-2)
  35. d’Eril G. M., Anesi A., Maggiore M., Leoni V. Biological variation of serum amyloid A in healthy subjects. Clin. Chem., 47: 1498-1499,  2001. (10.1093/clinchem/47.8.1498)
  36. Kimura M., Tomita Y., Imai T., Saito T., Katagiri A., Ohara-Mikami Y., Matsudo T., Takahashi K. Significance of serum amyloid A on the prognosis in patients with renal cell carcinoma. Cancer (Phila.), 92: 2072-2075,  2001. (10.1002/1097-0142(20011015)92:8<2072::AID-CNCR1547>3.0.CO;2-P)
  37. Glojnaric I., Casl M. T., Simic D., Lukac J. Serum amyloid A protein (SAA) in colorectal carcinoma. Clin. Chem. Lab. Med., 39: 129-133,  2001. (10.1515/CCLM.2001.022)
  38. Biran H., Friedman N., Neumann L., Pras M., Shainkin-Kestenbaum R. Serum amyloid A (SAA) variations in patients with cancer correlation with disease activity, stage, primary site, and prognosis. J. Clin. Pathol., 39: 794-797,  1986. (10.1136/jcp.39.7.794)
  39. Kaneti J., Winikoff Y., Zimlichman S., Shainkin-Kestenbaum R. Importance of serum amyloid A (SAA) level in monitoring disease activity and response to therapy in patients with prostate cancer. Urol. Res., 12: 239-241,  1984. (10.1007/BF00256147)
  40. Weinstein P. S., Skinner M., Sipe J. D., Lokich J. J., Zamcheck N., Cohen A. S. Acute phase proteins of tumor markers: the role of SAA, SAP, CRP and CEA as indicators of metastasis in a broad spectrum of neoplastic diseases. Scand. J. Immunol., 19: 193-198,  1984. (10.1111/j.1365-3083.1984.tb00919.x)
  41. Benson M. D., Cohen A. S. Serum amyloid A protein in amyloidosis, rheumatic and neoplastic diseases. Arthritis Rheum., 22: 36-42,  1979. (10.1002/art.1780220106)
  42. Rosenthal C. J., Sullivan L. M. Serum amyloid A to monitor cancer dissemination. Ann. Inter. Med., 91: 383-390,  1979. (10.7326/0003-4819-91-3-383)
  43. Schmidt U., Wagner H., Miethke T. CpG-DNA upregulates the major acute-phase proteins SAA and SAP. Cell. Microbiol., 1: 61-67,  1999. (10.1046/j.1462-5822.1999.00007.x)
  44. Huang D. P., Ho J. H. C., Chan W. K., Lau W. H., Lui M. Cytogenetics of undifferentiated nasopharyngeal carcinoma xenografts from southern Chinese. Int. J. Cancer, 43: 936-939,  1989. (10.1002/ijc.2910430535)
  45. Yip T. T. C., Ngan R. K. C., Lau W. H., Poon Y. F., Joab I., Cochet C., Cheng A. K. A possible prognostic role of immunoglobulin-G antibody against recombinant Epstein-Barr virus BZLF-1 transactivator protein ZEBRA in patients with nasopharyngeal carcinoma. Cancer (Phila.), 74: 2414-2424,  1994. (10.1002/1097-0142(19941101)74:9<2414::AID-CNCR2820740905>3.0.CO;2-8)
  46. Yip T. T. C., Lau W. H., Chan J. K. C., Ngan R. K. C., Poon Y. F., Lung C. W., Lo T. Y., Ho J. H. C. Prognostic significance of DNA flow cytometric analysis in patients with nasopharyngeal carcinoma. Cancer (Phila.), 83: 2284-2292,  1998. (10.1002/(SICI)1097-0142(19981201)83:11<2284::AID-CNCR7>3.0.CO;2-J)
Dates
Type When
Created 19 years, 11 months ago (Sept. 21, 2005, 7:52 p.m.)
Deposited 2 years, 7 months ago (Jan. 13, 2023, 4:24 p.m.)
Indexed 1 month ago (July 24, 2025, 7:31 a.m.)
Issued 21 years, 7 months ago (Jan. 1, 2004)
Published 21 years, 7 months ago (Jan. 1, 2004)
Published Online 21 years, 7 months ago (Jan. 20, 2004)
Published Print 21 years, 7 months ago (Jan. 1, 2004)
Funders 0

None

@article{Cho_2004, title={Identification of Serum Amyloid A Protein As a Potentially Useful Biomarker to Monitor Relapse of Nasopharyngeal Cancer by Serum Proteomic Profiling}, volume={10}, ISSN={1557-3265}, url={http://dx.doi.org/10.1158/1078-0432.ccr-0413-3}, DOI={10.1158/1078-0432.ccr-0413-3}, number={1}, journal={Clinical Cancer Research}, publisher={American Association for Cancer Research (AACR)}, author={Cho, William C. S. and Yip, Timothy T. C. and Yip, Christine and Yip, Victor and Thulasiraman, Vanitha and Ngan, Roger K. C. and Yip, Tai-Tung and Lau, Wai-Hon and Au, Joseph S. K. and Law, Stephen C. K. and Cheng, Wai-Wai and Ma, Victor W. S. and Lim, Cadmon K. P.}, year={2004}, month=jan, pages={43–52} }